Athena Countouriotis
CIK 1571469 · President & CEO · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TPTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
11080 ROSELLE STREET
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IOVA | Director | — | $13.78 | — | $0 | 9 | 2026-06-18 |
| BMRN | Director | 21,040 | $55.75 | $1.17M | $0 | 4 | 2026-06-04 |
| PASG | Director | 945 | $3.36 | $3.2K | $309.9K | 9 | 2026-05-21 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | President & CEO | 0 | $76.01 | $0 | -$7.44M | 8 | 2022-08-17 |
| Cardiff Oncology, Inc. (TROV) Delisted | Director | — | — | — | $0 | 2 | 2019-06-24 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | SVP, Chief Medical Officer | 15,000 | $4.36 | $65.4K | $0 | 2 | 2018-02-20 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | SVP and Chief Medical Officer | 45,977 | — | — | $0 | 8 | 2017-02-24 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Chief Medical Officer | — | $0.54 | — | $0 | 3 | 2014-11-12 |
Recent Filings · Page 2 of 5
45 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-12-28 | BMRN | Grant (A) | +2,180 | $0 | EDGAR |
| 2023-06-08 | IOVA | Grant (A) | — | $0 | EDGAR |
| 2023-05-26 | PASG | Grant (A) | — | $0 | EDGAR |
| 2022-08-17 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Disp (D) | −110,959 | -$8.43M | EDGAR |
| 2022-06-14 | IOVA | Grant (A) | — | $0 | EDGAR |
| 2022-05-31 | PASG | Grant (A) | — | $0 | EDGAR |
| 2022-02-11 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Mixed | +59,429 | -$107.8K | EDGAR |
| 2021-07-01 | IOVA | Grant (A) | — | $0 | EDGAR |
| 2021-05-28 | PASG | Grant (A) | — | $0 | EDGAR |
| 2021-02-11 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Mixed | — | -$8.06M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.